NucliThera files patent and trademark applications to support RadiuMeta development

NucliThera AS submitted a patent application and a trademark application in July 2026 in support of its RadiuMeta project. The filings form part of the company’s strategy to protect its innovations and establish a distinct identity for the project.

RadiuMeta focuses on developing novel alpha-emitting therapies for metastatic cancer. By investing in intellectual property alongside scientific development, NucliThera aims to strengthen the project’s foundation for future commercialisation and partnering.

About NucliThera AS: NucliThera is an R&D company developing targeted radionuclide therapies for cancer, including lymphoma and leukaemia. Its research combines therapeutic radionuclides with monoclonal antibodies or small molecules to deliver radiation to cancer cells while limiting damage to surrounding healthy tissue.
NucliThera’s research team is jointly led by Chief Scientific Officer Dr Ada RepettoLlamazares, Chief Technology Officer Dr Roy H. Larsen and Chief Medical Officer Professor
Emeritus Øyvind S. Bruland. Dr Larsen and Professor Bruland’s pioneering work includes the development of Xofigo, an alpha-emitting therapy for bone metastases from prostate cancer.

Contact:
Chairman Roy H. Larsen +47 920 16 487
Chief Medical Officer Øyvind S. Bruland +47 971 74 004